Skip to main content
Premium Trial:

Request an Annual Quote

In-Q-Tel Invests in Claremont to Accelerate Sample Prep Platform

NEW YORK (GenomeWeb News) – Claremont BioSolutions said today it has entered a strategic partnership with investment firm In-Q-Tel to accelerate commercialization of Claremont's Prep-on-a-Chip sample preparation platform.

The Upland, Calif.-based nucleic acid extraction and purification products firm added that In-Q-Tel also invested in the company but provided no further details.

Claremont is leveraging the mechanical energy of micromotors used in the cell phone industry to develop disposable sample prep devices that "efficiently lyse any cell type and simultaneously extract DNA or RNA." The devices are battery powered and are currently operated by hand. Use of a syringe or pipette transports the sample through a small chamber where the cells are lysed and nucleic acids are extracted in less than five minutes, Clarement said.

"The In-Q-Tel investment will aid us in our mission to multiplex and automate the handling of the devices, completing our development of the Prep-on-a-Chip platform," Claremont CEO Gary Blackburn said in a statement.

During the past year the company announced distribution deals covering Europe, Taiwan, South Korea, Japan, the UK, and Ireland.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.